Dishman Carbogen Amcis Ltd (DCAL) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a strong quarter in terms of operating profit and cash generation, driven by a favorable product mix with higher-margin development services.
- A significant improvement in profitability was observed, with EBITDA growing 64.4% YoY for the first half, reflecting the success of higher-margin projects and operational efficiencies.
- The Marketable Molecules segment, particularly the cholesterol and vitamin D analogue business, demonstrated robust growth of 85% YoY for the quarter, indicating strong market demand.
- Strategic integration between Carbogen Amcis (Switzerland) and Dishman (India) is progressing well, with unified sales, finance, and IT organizations aimed at eliminating duplication and enhancing productivity.
- The company is actively expanding its service offerings, notably in the ADC space through a collaboration with Celonic, to provide a one-stop-shop solution from antibody development to fill-finish, which is attracting significant customer interest.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.